Hikma Pharmaceuticals PLC HIK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- GBX1,571.00
- Day Range
- GBX1,557.00–1,594.00
- 52-Week Range
- GBX1,187.00–1,865.00
- Bid/Ask
- GBX1,136.00 / GBX1,738.00
- Shares Outstanding
- 206.97M
- Market Cap
- GBX327.01B
- Volume/Avg
- 291,406 / 904,043
Key Statistics
- Price/Earnings (Normalized)
- 10.05
- Price/Sales
- 1.36
- Dividend Yield (Trailing)
- 4.07%
- Dividend Yield (Forward)
- 4.07%
- Dividend Payment Schedule
- Apr, Sep
- Total Yield
- 4.07%
Company Profile
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Value
- Total Number of Employees
- 9,400
- Website
- https://www.hikma.com
Valuation
|
Metric
|
HIK
|
|---|---|
Price/Earnings (Normalized) | 10.05 |
Price/Book Value | 1.74 |
Price/Sales | 1.36 |
Price/Cash Flow | 6.88 |
Price/Earnings
HIK
Financial Strength
|
Metric
|
HIK
|
|---|---|
Quick Ratio | 1.02 |
Current Ratio | 1.98 |
Interest Coverage | 6.06 |
Quick Ratio
HIK
Profitability
|
Metric
|
HIK
|
|---|---|
Return on Assets (Normalized) | 8.97% |
Return on Equity (Normalized) | 19.99% |
Return on Invested Capital (Normalized) | 13.65% |
Return on Assets
HIK
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#j&w$<R | LOCK|TVSZL | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|j&b%$?hT | LOCK|pG@T@ | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|Z&^l@Km | LOCK|PC | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|%##%<cj | LOCK|w#t | $29B | |||
| Viatris Inc
VTRS
| LOCK|B>h$NZ | LOCK|@< | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|&p | LOCK|Z@^ | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|nj<PW@ | LOCK|tQ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|xmC&z< | LOCK|<!m | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|!jqpb% | LOCK|Bb^tj | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|zx?r?@H | LOCK|<> | $2B |
United States